Jin Yang Pharmaceutical Co. Ltd (007370) - Total Liabilities
Based on the latest financial reports, Jin Yang Pharmaceutical Co. Ltd (007370) has total liabilities worth ₩111.51 Billion KRW (≈ $75.57 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Jin Yang Pharmaceutical Co. Ltd to track the company's year-over-year net asset growth rate.
Jin Yang Pharmaceutical Co. Ltd - Total Liabilities Trend (2014–2025)
This chart illustrates how Jin Yang Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Jin Yang Pharmaceutical Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
Jin Yang Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Jin Yang Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
City Of London Investment Trust
LSE:CTY
|
UK | GBX138.28 Million |
|
Smr Utama Tbk
JK:SMRU
|
Indonesia | Rp682.09 Billion |
|
CLOUDR GROUP LTD.
F:H3L
|
Germany | €1.33 Billion |
|
Kishin Corporation
KO:092440
|
Korea | ₩12.86 Billion |
|
Jaba I Inversiones Inmobiliarias Socimi SA
MC:YABA
|
Spain | €11.98 Million |
|
Inventus Mining Corp
V:IVS
|
Canada | CA$1.14 Million |
|
Software Acquisition Group III Inc
NASDAQ:SWAG
|
USA | $20.07 Million |
|
360 Capital Mortgage REIT
AU:TCF
|
Australia | AU$875.00K |
Liability Composition Analysis (2014–2025)
This chart breaks down Jin Yang Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Jin Yang Pharmaceutical Co. Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jin Yang Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jin Yang Pharmaceutical Co. Ltd (2014–2025)
The table below shows the annual total liabilities of Jin Yang Pharmaceutical Co. Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩107.95 Billion ≈ $73.16 Million |
+0.24% |
| 2024-12-31 | ₩107.70 Billion ≈ $72.98 Million |
+255.16% |
| 2023-12-31 | ₩30.32 Billion ≈ $20.55 Million |
-17.75% |
| 2022-12-31 | ₩36.87 Billion ≈ $24.99 Million |
+11.10% |
| 2021-12-31 | ₩33.18 Billion ≈ $22.49 Million |
+52.46% |
| 2020-12-31 | ₩21.77 Billion ≈ $14.75 Million |
-11.56% |
| 2019-12-31 | ₩24.61 Billion ≈ $16.68 Million |
-12.14% |
| 2018-12-31 | ₩28.01 Billion ≈ $18.98 Million |
-10.98% |
| 2017-12-31 | ₩31.47 Billion ≈ $21.32 Million |
+13.85% |
| 2016-12-31 | ₩27.64 Billion ≈ $18.73 Million |
-0.31% |
| 2015-12-31 | ₩27.72 Billion ≈ $18.79 Million |
+82.37% |
| 2014-12-31 | ₩15.20 Billion ≈ $10.30 Million |
-- |
About Jin Yang Pharmaceutical Co. Ltd
Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers crivix tablets, Eszol tablets, atolan tablets, prescription drugs, and over-the-counter drugs. It also offers antilipidemic, antiplatelet, gastrointestinal, and respiratory agents; antithrombotics; NSAIDs; menopause symptoms treatment; and stomatological products. The company also exports i… Read more